Kodiak Sciences ($KOD) says Zenkuda and tabirafusp-ted matched Regeneron’s ($REGN) Eylea in a Phase 3 wet AMD trial.
Zenkuda also showed durable vision gains, with 54% of patients maintaining improvement for six months.
Kodiak Sciences $KOD +150%
Its eye-disease drugs Zenkuda and tabirafusp-ted met the primary endpoints in the pivotal Phase 3 DAYBREAK trial in wet AMD.
Kodiak plans to file Zenkuda for approval in Q4, backed by five positive Phase 3 studies.
Shares of biopharmaceutical company Kodiak Sciences Inc. were up more than 150% in the hour after the opening bell Monday morning after promising late-stage trials for a pair of experimental eye drugs that could be the firm’s first products to ever go to market.
Read more:
Two of Kodiak Sciences’ drug candidates have matched Eylea in a phase 3 clinical trial, positioning the biotech to seek FDA approval of one of the eye disease assets this year.